Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.65 |
| ▸ | SYK | P43405 | 16/20 | 0.63 |
| ▸ | CD63 | P08962 | 4/20 | 0.63 |
| ▸ | JAK2 | O60674 | 2/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | ROS1 | P08922 | 1/20 | 0.59 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.59 |
| ▸ | BTK | Q06187 | 1/20 | 0.59 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.59 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19998666 | 0.89 | AURKA (0.53) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL15551811 | 0.89 | AURKA (0.52) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL1542273 | 0.87 | AURKA (0.53) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL15551918 | 0.86 | SYK (0.69) | SYKCD63JAK2 | |
| SCHEMBL2482275 | 0.85 | AURKA (0.79) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL1542134 | 0.84 | AURKA (0.48) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL15551877 | 0.84 | SYK (0.57) | SYKCD63JAK2 | |
| SCHEMBL15551875 | 0.84 | SYK (0.57) | SYKCD63JAK2 | |
| SCHEMBL16820587 | 0.84 | AURKA (0.61) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL16848694 | 0.84 | SYK (0.53) | AURKASYKCD63JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023279938-A1 | 2,6,8-POLYSUBSTITUTED IMIDAZO[1,2-A]PYRAZINE, AND SYNTHESIS METHOD THEREFOR AND USE THEREOF | 无锡市第二人民医院 | 2023-01-12 | — | — | WO | disclosed |
| CN-113480543-B | 2,6, 8-polysubstituted imidazo [1,2-a ] pyrazine and synthetic method and application thereof | 无锡市第二人民医院 | 2022-05-17 | — | — | CN | disclosed |
| EP-3553065-A1 | HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2019-10-16 | — | — | EP | disclosed |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | AURKA 794/4885SYK 1/4885CD63 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.